Antibody drug conjugate ado trastuzumab emtansine:an updated review / 国际药学研究杂志

ABSTRACT

As a new design strategy of anticancer drugs,antibody-drug conjugates have become a research hotspot in recent years. In 2013,the successful launch of ado trastuzumab emtansine(Kadcyla)provided a new solution for second-line treatment with trastuzumab-resistant HER2-positive advanced breast cancer patients. Based on its excellent clinical performance and HER2′s overex?pressing in many tumors,Roche further attempts to expand it for the therapy of HER2-positive metastatic breast cancer of each line and neoadjuvant for early breast cancer treatment,as well as applications to gastric cancer and non-small cell lung cancer(NSCLC) treatment. In general,results are mixed. Its position as second-line drugs of is further established,but factors such as tumor heteroge?neity are still a big challenge. This paper reviews the recent progress in these areas after its launch.